NCT02455999

Dose-finding Study to Assess the Safety and Effect of SYL1001 in Patients With Ocular Pain

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 66 (actual)
• Sponsor: Sylentis, S.A. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The aim of this pilot study is to compare the analgesic effect of two strengths of SYL1001 eye drops versus placebo in patients with ocular pain associated with Dry Eye Syndrome. General and local tolerability are also evaluated.

Conditions

• Ocular Pain
• Dry Eye Syndrome

Interventions

Type	Name	Description
DRUG	SYL1001	SYL1001 eye drops dose C administration for 10 consecutive days
DRUG	SYL1001	SYL1001 eye drops dose D administration for 10 consecutive days
DRUG	Placebo	Placebo eye drops administration for 10 consecutive days

Timeline

• Start date: 2015-06-01
• Primary completion: 2016-03-01
• First posted: 2015-05-28
• Last updated: 2016-04-05

Locations

6 sites across 2 countries: Estonia, Spain